Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice

Transplant Immunology

Volumn 29, Issue 1-4, 2013, Pages 99-104

  Guo, Hao ^a   Wang, Wei ^a   Zhao, Na ^a   He, Xianghui ^a   Zhu, Liwei ^a   Jiang, Xueming ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac allograft; Decitabine; IL 35

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; INTERLEUKIN 35; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE THERAPY; GRAFT SURVIVAL; HEART GRAFT; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO GENE TRANSFER; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE; UPREGULATION;

5-AZA-2′-DEOXYCYTIDINE; AZA; CARDIAC ALLOGRAFT; CD4(+)CD25(+) TREG CELL; DECITABINE; DNA METHYLTRANSFERASE; DNMT; FCM; FLOW CYTOMETRY; IL-35; MIXED LEUKOCYTE REACTION; MLR; REGULATORY T CELLS; TREG;

ALLOGRAFTS; ANIMALS; AZACITIDINE; CD8-POSITIVE T-LYMPHOCYTES; ENZYME INHIBITORS; GENETIC THERAPY; GRAFT REJECTION; HEART TRANSPLANTATION; HEK293 CELLS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; PLASMIDS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84897082935     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2013.10.001     Document Type: Article

References (47)

1. Zhang Y., Zhen H., Yao W., Bian F., Mao X., Yang X., et al. Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells. Int J Immunopathol Pharmacol Jan-Mar 2013, 26(1):107-115.
2. Ciprandi G., Cuppari C., Salpietro A., Tosca M., Grasso L., Ri goli L., et al. Serum IL-23 in asthmatic children. J Biol Regul Homeost Agents Jan-Mar 2012, 26(1 Suppl.):S53-S61.
3. low immune regulatory T cells in allergic asthma: pathogenesis relevance of their FoxP3, GITR, CTLA-4 and FAS expressions. J Biol Regul Homeost Agents Oct-Dec 2012, 26(4):627-639.
4. G. Lee, H. Lee, S. Park, H. Jang, H. Bae. Bee venom attenuates experimental autoimmune encephalomyelitis through direct effects on CD4+CD25+Foxp3+ T cells. European Journal of Inflammation, Vol. 11, no. 1, 111-122.
5. Krausz L.T., Fischer-Fodor E., Major Z.Z., Fetica B. GITR-expressing regulatory T-cell subsets are increased in tumor-positive lymph nodes from advanced breast cancer patients as compared to tumor-negative lymph nodes. Int J Immunopathol Pharmacol Jan-Mar 2012, 25(1):59-66.
6. Michael Maria, Shimoni Avichai, Nagler Arnon Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol 2013, volume 2013. [Article ID 608951, 9 pages].
7. Pillai Meenu R., Collison Lauren W., Wang Xiaohua, Finkelstein David, Rehg Jerold E., Boyd Kelli, et al. The plasticity of regulatory T cell function. J Immunol 2011, 187:4987-4997.
8. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569. [PubMed: 18033300].
9. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007, 37:3021-3029. [PubMed: 17874423].
10. Devergne O., Hummel M., Koeppen H., Le Beau M.M., Nathanson E.C., Kieff E., et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 1996, 70:1143-1145.
11. Devergne O., Birkenbach M., Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci U S A 1997, 94:12041-12046. [PubMed: 9342359].
12. Collison L.W., Pillai M.R., Chaturvedi V., Vignali D.A. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009, 182:6121-6128.
13. Huang C.H., Loo E.X., Kuo I.C., Soh G.H., Goh D.L., Lee B.W., et al. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol 2011, 187:462-471.
14. Wirtz S., Billmeier U., Mchedlidze T., Blumberg R.S., Neurath M.F. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. J Gastroenterol 2011, 141:1875-1886.
15. Whitehead G.S., Wilson R.H., Nakano K., Burch L.H., Nakano H., Cook D.N. IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 2012, 129:207-215.
16. Torgerson Troy R., Genin Anna, Chen Chunxia, Zhang Mingce, Zhou Bin, Añover-Sombke Stephanie, et al. FOXP3 Inhibits Activation-Induced NFAT2 Expression in T Cells Thereby Limiting Effector Cytokine Expression. J Immunol 2009, 183(2):907-915.
17. + regulatory T cells. J Exp Med 2005, 201:1061-1067.
18. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
19. + regulatory T cells. J Immunol 2007, 178:280-290.
20. Lal G., Zhang N., van der Touw W., Ding Y., Ju W., Bottinger E.P., et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009, 182:259-273.
21. Cp Abbott, Es Lindsey, Creech O., Dewitt C.W. A technique for heart transplantation in the rat. J. Arch Surg 1964, 89:645-652.
22. Liu Fengchun, Mo Kang Sang Heterotopic heart transplantation in mice. J Vis Exp 2007, 2007(6):238.
23. + regulatory T cells. J Immunol 2005, 174:6993-7005.
24. + regulatory T cells in inflammatory bowel disease. J Dig Dis 2011, 12:286-294.
25. Chaturvedi Vandana, Collison Lauren W., Guy Clifford S., Workman Creg J., Vignali Dario A.A. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011, 186:6661-6666.
26. Vojdani A., Lambert J. The role of Th17 in neuroimmune disorders: target for CAM therapy. Part I. Evid Based Complement Alternat Med 2011, 9272974.
27. + Treg cells. J Biol Regul Homeost Agents 2010, 24(2):131-135.
28. Ye Sunyi, Wu Jian, Zhou Lin, Lv Zhen, Xie Haiyang, Zheng Shusen Interleukin-35: the future of hyperimmune-related diseases?. J Interferon Cytokine Res 2013, 33(6):285-291.
29. Collison L.W., Chaturvedi V., Henderson A.L., Giacomin P.R., Guy C., Bankoti J., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010, 11:1093-1101.
30. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10(12):1969-1980.
31. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188(2):287-296.
32. Tang Q., Adams J.Y., Tooley A.J., Bi M., Fife B.T., Serra P., et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2005, 7(1):83-92.
33. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 2006, 24:209-226.
34. Zuo Tao, Liu Runhua, Zhang Huiming, Chang Xing, Liu Yan, Wang Lizhong, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007, 117(12):3765-3773.
35. (+) T cell effector function. J Immunol 2003, 171:1216-1223.
36. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor FOXP3. Science 2003, 299:1057-1061.
37. (+) regulatory T cells. Int Immunol 2004, 16:1643-1656.
38. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Faderl S., Issa J.P., et al. Results of decitabine (5-aza-2_deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003, 98:522-528.
39. + T cells and prevents the occurrence of diabetes in mice. J Mol Med 2009, 87:1191-1205.
40. Lubberts E., Koenders M.I., van den Berg W.B. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2004, 7:29-37.
41. Chu C.Q., Swart D., Alcorn D., Tocker J., Elkon K.B. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007, 56:1145-1151.
42. Silverman L., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20(10):2429-2440.
43. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921 and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24(24):3895-3903.
44. Sudan N., Rossetti J.M., Shadduck R.K. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006, 107(8):1839-1843.
45. Jabbour E., Giralt S., Kantarjian H., Garciamanero G., Jagasia M., Kebriaei P., et al. Low-dose azacitidine after allogenic stem cell transplantation for acute leukemia. Cancer 2009, 115(9):1899-1905.
46. Pinto A., Zagonei V. 5-Aza-2-deoxycytidine (decibabine) and 5-azacytidine in the treatment of acute myeloid leukemia and myelodysplastic syndromes: past, present and future trends. Leukemia 1993, 7(1):51-60.
47. Momparler R.L., Bouchard J., Samson J. Induction of differentiation and inhibition of DNA methylation in HL60 myeloid leukemic cells by 5-Aza-2-deoxycytidine. Leuk Res 1985, 9(11):1361-1366.